Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSina BeerBBBritta BesemerCLClaudia Lengerke

Discussion

Loading...

Member takes

Overview

Observational analysis reveals distinct phenotypic profiling of circulating tumor plasma cells, suggesting immune resistance in multiple myeloma.

Key Points

  • CTPC counts significantly increase with disease progression, highlighting their role in myeloma diagnostics.
  • Phenotypic profiling showed changes in CD markers with increased CD16 expression in multiple myeloma patients.
  • Assessment using 36-parameter spectral flow cytometry data from MGUS and NDMM patients captures CTPC evolution.
  • Findings may enable new strategies for monitoring and treating multiple myeloma based on CTPC profiles.

Cite This Study

Beer et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1e4https://doi.org/10.1182/blood-2025-3914
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  2. 2Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma2025
  3. 3Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  4. 4Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients2025
  5. 5Surface protein-focused gene expression analysis identifies prognostic immunophenotypes in newly diagnosed multiple myeloma2025